11/15
08:45 am
cero
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
High
Report
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
11/11
08:15 am
cero
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
High
Report
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
10/21
04:58 pm
cero
CERo Therapeutics files to sell 713.6M shares of common stock for holders [Seeking Alpha]
Medium
Report
CERo Therapeutics files to sell 713.6M shares of common stock for holders [Seeking Alpha]
10/21
09:00 am
cero
CERo Therapeutics, Inc. Provides Corporate Update
Low
Report
CERo Therapeutics, Inc. Provides Corporate Update
10/2
09:15 am
cero
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
High
Report
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
9/25
09:34 am
cero
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 [Yahoo! Finance]
High
Report
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 [Yahoo! Finance]
9/25
09:17 am
cero
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
Medium
Report
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236